Medicus Pharma Identifies 200 µg D-MNA Patch as Lead Dose for SkinJect® After Phase 2 Results
Event summary
- Medicus Pharma published abridged Phase 2 results for SkinJect®, identifying the 200 µg D-MNA patch as the lead development dose.
- The study enrolled 90 patients across 10 U.S. sites, with no treatment discontinuations or withdrawals.
- Results support an FDA-authorized Phase 2b study (SKNJCT-005) in Gorlin syndrome patients with multiple BCC lesions.
- Medicus estimates a U.S. total addressable market of approximately $1.1 billion for SkinJect® in Gorlin syndrome.
The big picture
Medicus Pharma's strategic shift to focus on Gorlin syndrome with SkinJect® aims to capitalize on the rare disease's regulatory incentives and differentiated reimbursement profile. The company's capital-efficient development strategy seeks to balance internal progress with potential partnerships for broader applications in nodular BCC. The Phase 2 results provide a scientific foundation for these efforts, but execution risks and competitive dynamics remain critical factors.
What we're watching
- Regulatory Pathway
- Whether the FDA will grant Orphan Drug Designation and Rare Pediatric Disease designation for SkinJect®, which could provide significant regulatory and economic benefits.
- Commercial Viability
- The pace at which Medicus can secure strategic partnerships to advance SkinJect® in nodular basal cell carcinoma, given the competitive landscape.
- Clinical Execution
- How the SKNJCT-005 study progresses and whether it delivers robust, decision-grade clinical data to support a potential NDA submission.